Waters Corp ((WAT)) has held its Q1 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Waters Corp’s latest earnings call struck an upbeat tone as management showcased a strong start to the year, a clean beat on revenue and earnings, and faster‑than‑planned progress integrating the newly acquired BD assets. While executives flagged respiratory testing weakness, China pressures, and higher interest costs, they framed these as manageable headwinds against a stronger growth and margin story.
Robust Q1 Revenue and Organic Growth Momentum
Waters reported total Q1 revenue of $1.267 billion, with legacy organic revenue of $747 million rising 13% as reported and 11% in constant currency versus last year. Management emphasized that orders outpaced sales, suggesting a healthy demand pipeline across core analytical instruments and consumables.
Acquired Businesses Deliver Above‑Plan Performance
The newly acquired Biosciences and Diagnostic Solutions units generated $520 million of revenue during the owned period, about $40 million above guidance. Biosciences contributed roughly $230 million with an estimated 7% as‑reported growth, while Diagnostic Solutions added $288 million at an estimated 8% growth.
EPS Beat Underscores Margin Outperformance
Adjusted EPS climbed 20% year over year to $2.70, beating the high end of guidance by $0.35 as gross and operating margins came in well ahead of expectations. Adjusted gross margin reached 54.7% and operating margin 23.6%, with both roughly 200 basis points better than management’s prior forecast.
Upgraded 2026 Outlook Signals Confidence
On the back of the strong quarter, Waters raised its 2026 organic constant‑currency revenue growth outlook to 6.5%–8%. Total reported revenue is now expected between about $6.405 billion and $6.455 billion, with adjusted EPS nudged up by $0.10 to a range of $14.40–$14.60, implying 10%–11% growth.
Synergy Capture Tracking to Ambitious Targets
Management reported that integration synergies from the BD acquisition are progressing as planned, with $55 million of cost savings slated for 2026. Waters is also targeting $50 million of revenue synergies this year, including $35 million from the acquired franchises, with restructuring savings expected to begin flowing through the P&L in the third quarter.
180‑Day Commercial Revamp Drives Early Wins
A rapid 180‑day commercial plan is underway to sharpen forecasting, boost field activity, and tighten pricing discipline across the enlarged company. Early efforts, including more sales calls and expanded deal desk support, uncovered roughly 700 out‑of‑compliance U.S. diagnostics contracts, representing a double‑digit million annual revenue opportunity.
New Products and Regulatory Wins Strengthen Portfolio
Waters highlighted several milestones, including CE marking for the BACTEC FXI blood culture system, which offers faster detection and a 60‑sample loading capacity. The company also launched Microflow LC Chemistry Columns and the omniDAWN detector, aiming to deliver up to twice the sensitivity in bioseparations and to extend its light‑scattering technology edge.
Equipment Replacement and Service Initiatives Offer Upside
The company has identified about 22,000 instruments as ripe for replacement, including 12,000 BACTEC systems, with more than half older than five years. Waters expects new service plan attachment programs to add at least $20 million in revenue over the next five years and has accelerated the BACTEC FXI rollout in the U.S. and Europe by several months.
Respiratory Testing Weakness Creates Temporary Drag
A soft respiratory season, notably a weak flu backdrop, produced roughly a $20 million headwind in the quarter. Management said this translated into about a 4.5% respiratory‑related drag on divisional pro forma growth for Advanced Diagnostics over the full quarter.
China DRG Reform and Export Rules Hit Growth
China remained a pain point as reimbursement reforms and export constraints weighed on multiple businesses, particularly high‑parameter instruments. Flow Clinical China revenue fell 25%, Biosciences in Asia declined by the high teens, and Diagnostic Solutions China revenue was down 12%, prompting a push to further localize the portfolio.
Mixed Pro Forma Trends in Acquired Units
On a full quarter pro forma basis, Biosciences revenue slipped 1%, an improvement from the 10% decline seen in the fourth quarter of 2025. Advanced Diagnostics grew just 1% pro forma, or 3% when including the clinical business unit, with management focused on operational fixes and commercial initiatives to lift growth.
GAAP Loss and Deal Costs Cloud the Bottom Line
Despite strong adjusted earnings, Waters posted a GAAP diluted loss per share of $0.87, driven by acquisition‑related accounting charges such as intangible amortization and inventory step‑up. Free cash flow was $42 million in the quarter, constrained by transaction costs and the timing of net cash settlement with the seller.
Instrument and Academic Spending Still Under Pressure
Within Biosciences, instruments continue to face pressure from soft U.S. academic and government spending, compounded by China‑related constraints. While reagents and selected instrument lines grew, management noted that the broader instrument recovery is uneven across geographies and end markets.
Higher Interest and Share Count Temper Near‑Term EPS
Net interest expense reached $38 million in Q1, with full‑year interest costs now expected at about $186 million following the leveraged acquisition. Combined with a higher share count, these factors limit second quarter EPS growth to a guided flat to 3.4% increase before cost and revenue synergies ramp from the third quarter onward.
Conservative Back‑Half Assumptions Despite Strong Start
Management stressed that second‑half 2026 assumptions have been deliberately derisked to reflect macro uncertainty and known headwinds. The company set its second‑half organic constant‑currency growth guide at roughly 6%, below the pace implied by prior guidance even after the first quarter beat, signaling a cautious stance.
Guidance: Solid Growth, Margin Expansion, and Synergy Upside
Waters’ full‑year 2026 outlook now assumes 6.5%–8% organic constant‑currency revenue growth, with total revenue of about $6.405 billion to $6.455 billion and adjusted EBIT margin at 28.2%. The company expects roughly $3.035 billion of 2026 revenue from Biosciences and Diagnostic Solutions, net interest expense near $186 million, a 16% tax rate, $55 million in cost synergies, and about $50 million in revenue synergies, while Q2 guidance calls for 6%–8% organic growth and adjusted EPS of $2.95–$3.05.
Waters’ earnings call painted a picture of a company executing well on a complex integration while steadily improving growth and profitability. Investors will watch whether management can convert early synergy wins, product launches, and replacement opportunities into sustained mid‑single‑digit to high‑single‑digit growth, even as China, respiratory testing, and higher interest costs continue to test the story.